| Revista: | The brazilian journal of infectious diseases |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000290692 |
| ISSN: | 1413-8670 |
| Autores: | Carvalho, Carlos Roberto Ribeiro1 Franca, Suelene Aires2 |
| Instituciones: | 1Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo. Brasil 2Universidade Federal de Goias, Hospital das Clinicas, Goiania, Goias. Brasil |
| Año: | 2002 |
| Periodo: | Ago |
| Volumen: | 6 |
| Número: | 4 |
| Paginación: | 157-163 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Caso clínico, analítico |
| Resumen en inglés | ABSTRACT OBJECTIVES: Evaluation of the effectiveness, safety and tolerability of gatifloxacin in the treatment of outpatients with community-acquired pneumonia (CAP). STUDY DESIGN: A prospective, multicenter, non-comparative clinical study carried out in Brazil. Voluntary, unpaid physician participation contributed to an unbiased study design. PATIENTS: Adult outpatients with clinical diagnosis of CAP. REGIMEN: Gatifloxacin, 400 mg PO once daily for 7 to 14 days. STUDY PROCEDURES: Initial clinical assessment, at the first day of gatifloxacin therapy; final evaluation after 7 to 14 days of treatment. RESULTS: According to the physicians' assessments 97.3% of patients were cured or improved after gatifloxacin treatment. The incidence of adverse events was low and the most commonly reported events were nausea and dyspepsia. CONCLUSIONS: Gatifloxacin, 400 mg PO once daily for 7 to 14 days, is effective and safe in the treatment of patients with CAP |
| Disciplinas: | Medicina |
| Palabras clave: | Farmacología, Microbiología, Terapéutica y rehabilitación, Gatifloxacina, Pneumonia |
| Keyword: | Medicine, Microbiology, Pharmacology, Therapeutics and rehabilitation, Gatifloxacin, Pneumonia |
| Texto completo: | Texto completo (Ver HTML) |
